Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Asset Resilience Ratio
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has an Asset Resilience Ratio of 0.81% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Hangzhou TianMuShan Pharmaceutical Enter for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2011)
This chart shows how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's Asset Resilience Ratio has changed over time. See 600671 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600671 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥3.50 Million | 0.81% |
| Total Liquid Assets | CN¥3.50 Million | 0.81% |
Asset Resilience Insights
- Limited Liquidity: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd maintains only 0.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
Novo Nordisk A/S
CO:NOVO-B |
Drug Manufacturers - General | 0.09% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 10.04% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Annual Asset Resilience Ratio for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2011)
The table below shows the annual Asset Resilience Ratio data for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2011-12-31 | 0.31% | CN¥1.12 Million ≈ $164.07K |
CN¥357.84 Million ≈ $52.36 Million |
+0.23pp |
| 2010-12-31 | 0.08% | CN¥253.08K ≈ $37.03K |
CN¥319.79 Million ≈ $46.80 Million |
+0.07pp |
| 2009-12-31 | 0.00% | CN¥16.29K ≈ $2.38K |
CN¥328.27 Million ≈ $48.04 Million |
-0.01pp |
| 2008-12-31 | 0.02% | CN¥68.44K ≈ $10.01K |
CN¥369.08 Million ≈ $54.01 Million |
-1.99pp |
| 2007-12-31 | 2.01% | CN¥8.33 Million ≈ $1.22 Million |
CN¥414.09 Million ≈ $60.59 Million |
+1.99pp |
| 2005-12-31 | 0.03% | CN¥95.01K ≈ $13.90K |
CN¥372.71 Million ≈ $54.54 Million |
0.00pp |
| 2004-12-31 | 0.03% | CN¥94.19K ≈ $13.78K |
CN¥357.85 Million ≈ $52.37 Million |
-8.14pp |
| 2001-12-31 | 8.17% | CN¥33.40 Million ≈ $4.89 Million |
CN¥408.75 Million ≈ $59.81 Million |
-0.29pp |
| 2000-12-31 | 8.46% | CN¥34.34 Million ≈ $5.03 Million |
CN¥405.88 Million ≈ $59.39 Million |
+3.02pp |
| 1999-12-31 | 5.44% | CN¥18.50 Million ≈ $2.71 Million |
CN¥339.78 Million ≈ $49.72 Million |
-1.32pp |
| 1997-12-31 | 6.76% | CN¥20.00 Million ≈ $2.93 Million |
CN¥295.69 Million ≈ $43.27 Million |
-2.66pp |
| 1996-12-31 | 9.43% | CN¥24.45 Million ≈ $3.58 Million |
CN¥259.33 Million ≈ $37.95 Million |
-14.31pp |
| 1995-12-31 | 23.73% | CN¥62.43 Million ≈ $9.13 Million |
CN¥263.02 Million ≈ $38.49 Million |
+7.77pp |
| 1994-12-31 | 15.96% | CN¥30.66 Million ≈ $4.49 Million |
CN¥192.12 Million ≈ $28.11 Million |
+1.82pp |
| 1993-12-31 | 14.15% | CN¥16.06 Million ≈ $2.35 Million |
CN¥113.50 Million ≈ $16.61 Million |
-- |
About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, hard capsules, and other health foods. I… Read more